Latanoprost (free acid)-d4

Latanoprost (free acid)-d4 is intended for use as an internal standard for the quantification of latanoprost (free acid) (Cay-16811) by GC- or LC-MS. Latanoprost (free acid) is a derivative of prostaglandin F2alpha (PGF2alpha, Cay-16010, Cay-16020), an FP receptor agonist, and an active metabolite of the prodrug latanoprost (Cay-16812). It selectively binds to the FP receptor (Ki = 0.098 µM) over the EP1, EP2, EP3, and EP4 receptors (Kis = 2.06, 39.667, 7.519, and 75 µM, respectively), as well as the DP, IP, and TP receptors (Kis = >20, >90, and >60 µM, respectively). It induces phosphoinositide turnover in isolated human ciliary muscle and human trabecular meshwork cells, mouse NIH3T3 fibroblasts, and rat A7r5 vascular smooth muscle cells, which all endogenously express FP receptors (EC50s = 124, 35, 32, and 35 nM, respectively), as well as HEK293 cells expressing human ocular FP receptors (EC50 = 45.7 nM). It also increases intracellular calcium levels in hEP1-5/293-AEQ17 cells expressing EP1 receptors in an aequorin-based calcium assay (EC50 = 119 nM). Latanoprost (free acid) induces contraction of isolated cat iris sphincter smooth muscle (EC50 = 29.9 nM).Formal Name: 9alpha,11alpha,15R-trihydroxy-17-phenyl-18,19,20-trinor-prost-5Z-en-1-oic-3,3,4,4-d4 acid. CAS Number: 1224443-47-3. Synonyms: Lat-FA-d4, PhXA 85-d4, 17-phenyl-13,14-dihydro trinor Prostaglandin F2alpha-d4. Molecular Formula: C23H30D4O5. Formula Weight: 394.5. Purity: >99% deuterated forms (d1-d4). Formulation: (Request formulation change), A solution in methyl acetate. Solubility: DMF: 50 mg/ml, DMSO: 50 mg/ml, Ethanol: 100 mg/ml, PBS (pH 7.2): .5 mg/ml. SMILES: O[C@@H]1[C@H](C/C=C\C([2H])([2H])C([2H])([2H])CC(O)=O)[C@@H](CC[C@@H](O)CCC2=CC=CC=C2)[C@H](O)C1. InChi Code: InChI=1S/C23H34O5/c24-18(13-12-17-8-4-3-5-9-17)14-15-20-19(21(25)16-22(20)26)10-6-1-2-7-11-23(27)28/h1,3-6,8-9,18-22,24-26H,2,7,10-16H2,(H,27,28)/b6-1-/t18-,19+,20+,21-,22+/m0/s1/i2D2,7D2. InChi Key: HNPFPERDNWXAGS-GPPKKVIBSA-N.